FiercePharma welcomes a new editor

I'm excited to announce the newest member of the Fierce editorial staff. Christe Bruderlin-Nelson joins us today as a regular editor for FiercePharma. Christe has previously written for a number of industry publications such as Genetic Engineering News, FDA News, Pharmaceutical Technology, IVD Technology, and more. She has also worked directly with leading drug developers such as Amgen, Fleet Pharmaceuticals and SRI International. With a great voice and unique background in the world of drug development, I'm sure you'll come to appreciate her take of the day's news and insightful analysis of industry trends.
 
If you would like to join me in welcoming Christe, you can contact her here.
 
Best,
Sean Griffey
Publisher, FiercePharma
 
P.S. Thanks to everyone who answered my informal straw poll about the upcoming DIA annual meeting yesterday. Judging from the responses, it is shaping up to be a great show. One reader claims to have been to 18 of the previous 43 annual meetings. Can anyone beat that?

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.